Ultrasound for Assessment of Extubation Readiness

Sponsor
Mount Sinai Hospital, Canada (Other)
Overall Status
Completed
CT.gov ID
NCT04957264
Collaborator
(none)
45
1
30.9
1.5

Study Details

Study Description

Brief Summary

Preterm infants are at high-risk for the negative implications of both prolonged mechanical ventilation and extubation failure. Pre-extubation assessments of lung parenchyma and diaphragmatic function of these infants can be useful adjunctive tool for prediction of extubation readiness.

The aim of this study is to assess the sensitivity and specificity of lung ultrasound and diaphragmatic function evaluation in prediction of extubation readiness in mechanically ventilated neonates born at < 28 weeks gestational age.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Study Design and setting:This is a prospective descriptive pilot study that will be conducted on infants born at < 28 weeks gestation who meet eligibility criteria and are admitted to the Neonatal intensive care at Mount Sinai Hospital. Enrolment of eligible infants will start after obtaining approval from Mount Sinai Research Ethics Board and parent's consent.

    Time of assessment: Parents of infants on invasive mechanical ventilation who are eligible for the study will be approached for consent. Once the decision made by attending physician to extubate the infant, Chest ultrasound (Lung ultrasound + diaphragmatic function assessment) will be done. Chest ultrasound will be done before next feeding to avoid any interference of a full stomach on diaphragmatic assessment.

    Study procedure: Decisions about extubation will be as per the clinical judgment of the physician in-charge of the infant and will not in any way based on Chest ultrasound measurements. A lung ultrasound combined with diaphragmatic function assessment will be done by one of the investigators prior to extubation. The result of Chest ultrasound will be masked for the clinical team to avoid any influence of the Chest ultrasound result on the extubation decision. On the other hand, if the attending physician requests Chest ultrasound for the purpose of the ongoing clinical management or to help with making extubation decision then the result of the study will be disclosed to the physician and this infant will be excluded from the study.

    A random sample of 20% of eligible infants will have lung ultrasound scoring and diaphragmatic function assessment done twice by 2 operators (with various levels of Chest ultrasound expertise). None of the operator will be aware of the result of Chest ultrasound done by the other operator for the same patient. Lung ultrasound severity score, diaphragmatic thickness fraction and diaphragmatic excursion will be calculated. Inter-rater agreement will be assessed using raw percentage of agreement (Pa), Cohen's and Kappa (κ), and G wet agreement coefficient (AC1). Intra-class correlation will be determined for variables with continuous measurements (mixed factorial design). High-resolution linear and curvi-linear ultrasound probes of 20-5 and 10-3 MegaHertZ will be used to assess lung ultrasound score and to measure diaphragmatic thickness and diaphragmatic excursion [amplitude] respectively using both B-mode and M-mode.

    Lung ultrasound assessment technique: Chest ultrasound will be performed in a standardized manner. A longitudinal scan of the anterior and lateral chest walls will be performed. Three chest areas for each side (upper anterior, lower anterior, and lateral) will be assessed. Each area will have a score of 0 to 4 points with the total score ranges from 0 to 24 which inversely correlating with lung aeration.

    Diaphragmatic assessment technique: Diaphragm assessment will be performed in the supine position. For measuring diaphragmatic excursion, the curvilinear probe will be placed on the lower intercostal spaces between the mid-clavicular and anterior axillary lines on the right side. Using the B mode, the proper exploration line of the diaphragm will be detected by directing the beam perpendicular to the posterior third of each hemi-diaphragm. By M mode, the cyclic caudal diaphragmatic displacement with respiration will be measured as the perpendicular distance between the most caudal point of the liver or spleen at the end of expiration and the end of inspiration. The average of three respiratory cycles will be taken.

    The assessment of the diaphragmatic efficiency as a pressure generator will be evaluated using the diaphragmatic thickness fraction. Diaphragmatic thickness will be measured at the apposition zone which can be obtained by placing the linear transducer above the 10th rib in the mid-axillary or anterior axillary lines in the right intercostal spaces. By B-mode, three distinct layers will be seen, the diaphragm as a hypo-echoic area bordered by two clear echogenic lines of the pleural membrane (upper line) and the peritoneal membrane (lower line). Using M-mode tracing, inspiratory diaphragmatic thickness will be measured as the maximum perpendicular distance between pleural and peritoneal layers and by the same way expiratory diaphragmatic thickness will be recorded. diaphragmatic thickness Fraction will be calculated using the following formula: diaphragmatic thickness Fraction equal to [(inspiratory thickness _ expiratory thickness)/expiratory thickness] x100. The average of the calculated diaphragmatic thickness Fraction from three respiratory cycles will be estimated. All Chest Ultrasound assessments will be undertaken using a standard aseptic technique.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    45 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Assessment of Extubation Readiness in Preterm Infants Using Chest Ultrasound
    Actual Study Start Date :
    Oct 22, 2019
    Actual Primary Completion Date :
    May 20, 2022
    Actual Study Completion Date :
    May 20, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Accuracy of chest ultrasound in Prediction of extubation readiness in neonates born at less than 28 weeks gestation. [2 year]

      Chest ultrasound will be performed prior to extubation and Lung aeration will be scored based on three chest areas for each side (upper anterior, lower anterior and lateral) and a score of 0-to-4 point will be given for each area. The minimum score = 0 point and the maximum score = 24 points. successful extubation was defined as remained extubated at day 3 post extubation

    Secondary Outcome Measures

    1. Assess the Diaphragmatic Thickness Fraction and Diaphragmatic Excursion in preterm infants [2 year]

      Assessment of Diaphragmatic Thickness in millimetres. Assessment of Diaphragmatic Excursion in millimetres.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    12 Hours and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Infants who are born at < 28 weeks Gestational Age,

    • Admitted to the neonatal intensive care at Mount Sinai Hospital

    • Receiving invasive mechanical ventilation.

    Exclusion Criteria:
    • Infants who are born at >27 weeks Gestational Age,

    • On non-invasive mechanical ventilation

    • Infants having congenital or chromosomal abnormalities,

    • Infants intubated for < 12 hours

    • Infants who have neurological insult, pneumothorax, or under muscle relaxant.

    • If parents declined the consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mount Sinai Hospital Toronto Ontario Canada M5G1X5

    Sponsors and Collaborators

    • Mount Sinai Hospital, Canada

    Investigators

    • Study Chair: Adel Mohamed, MD, Mount Sinai Hospital- Toronto, ON, Canada

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mount Sinai Hospital, Canada
    ClinicalTrials.gov Identifier:
    NCT04957264
    Other Study ID Numbers:
    • 19-0211-E
    First Posted:
    Jul 12, 2021
    Last Update Posted:
    Jul 20, 2022
    Last Verified:
    Oct 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mount Sinai Hospital, Canada
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 20, 2022